Featured video

Ordering information

L3000001,L3000008,L3000015,L3000075,L3000150

Gentle with low toxicity

When developing Lipofectamine 3000 reagent, we optimized all four steps in the transfection process and combined our most advanced lipid nanoparticle technologies together. The superior transfection performance allows you to reduce the reagent dose and lower any potential toxicity risk when working with your cell line.

Figure 3. Each reagent was used to transfect HeLa cells in a 96-well format at the indicated doses with an emerald green fluorescent protein (GFP)–expressing vector. Analysis was performed 48 hours posttransfection utilizing flow cytometry to determine percent transfection efficiency and the intensity of GFP expression. Lipofectamine 3000 reagent delivered higher efficiency and protein expression than both Lipofectamine 2000 reagent and Invitrogen Lipofectamine LTX Reagent.

Enhance your cancer research

Using the most biologically relevant cell lines provides the most relevant answers to your research questions. The superior cell spectrum and higher transfection efficiency of Lipofectamine 3000 reagent enables excellent flexibility to use your cell line of choice in your studies.

Lipofectamine 3000 reagent demonstrates significantly higher transfection performance compared to leading transfection reagents, such as Lipofectamine 2000 reagent, in a panel of cancer cells derived from various tissues. While only 25% of the selected cancer cell line panel would be considered easy to transfect (>50% transfection efficiency) with Lipofectamine 2000 reagent, 60% of the panel is easy to transfect with Lipofectamine 3000 reagent.

Figure 4. Lipofectamine 2000 reagent and Lipofectamine 3000 reagent were used to transfect 17 cell lines with a GFP-expressing plasmid in a 24-well plate format, using 0.5 µg plasmid/well and the recommended protocols for each reagent. GFP expression was analyzed 48 hours posttransfection. Each condition was tested in triplicate, and the data points show the mean transfection efficiency + SD.

Figure 5. Reprogramming efficiency of Lipofectamine 3000 reagent compared to electroporation. BJ fibroblasts as well as neonatal (HDFn) and adult (HDFa) human dermal fibroblasts were reprogrammed to iPSCs by transfection of Epi5 vectors using either Lipofectamine 3000 reagent or the Invitrogen Neon Transfection System. Colonies were (A) visualized by brightfield microscopy and (B) stained for alkaline phosphatase.

Improve genome editing outcomes

Lipofectamine 3000 reagent was developed to break through the boundaries of delivery and facilitate new technologies, such as genome engineering, in more biologically relevant systems. With this reagent, Invitrogen GeneArt TALs and CRISPR sequences target the AAVS1 locus in HepG2 and U2OS cells, and show improved transfection efficiency, mean fluorescence intensity, and genomic cleavage. These advancements in delivery help minimize painstaking downstream workflows, enable easier stem cell manipulation, and enhance site-specific insertion of transgenes into the cellular genome.

“Excellent. Far better transfection efficiency than Lipofectamine® 2000 when we compared them head-to-head."—Suzanne Ridges, PhD, University of Kentucky

“We were very happy and surprised to see Lipofectamine® 3000 reagent provide a more than 10-fold difference in transfection efficiency in our difficult-to-transfect cell line. There was even a reduction in cell death. Awesome results!—Rui Eduardo Castro, PhD, University of Lisbon

“Spectacular increase in transfection efficiency and dramatic decrease in cell toxicity. Way ahead of the others!” —Emmanuel Boucrot, PhD, Principal Investigator, University College London

“I tried Lipofectamine® 3000 on several commonly used human and mouse tumor cell lines (293T, HeLa, A549, NIH3T3)….Lipofectamine® 3000 has a reduced cytotoxicity in comparison to Lipofectamine®2000, which is a great improvement to me…” —Dr. Jianming Xu, Researcher at the German Cancer Research Center, Heidelberg, Germany